WO2016005995A3 - Glycol free stable liquid compositions of bendamustine - Google Patents

Glycol free stable liquid compositions of bendamustine Download PDF

Info

Publication number
WO2016005995A3
WO2016005995A3 PCT/IN2015/000279 IN2015000279W WO2016005995A3 WO 2016005995 A3 WO2016005995 A3 WO 2016005995A3 IN 2015000279 W IN2015000279 W IN 2015000279W WO 2016005995 A3 WO2016005995 A3 WO 2016005995A3
Authority
WO
WIPO (PCT)
Prior art keywords
bendamustine
stable liquid
liquid compositions
free stable
glycol free
Prior art date
Application number
PCT/IN2015/000279
Other languages
French (fr)
Other versions
WO2016005995A2 (en
Inventor
Kocherlakota Chandrashekhar
Banda Nagaraju
Original Assignee
Leiutis Pharmaceuticals Pvt. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiutis Pharmaceuticals Pvt. Ltd. filed Critical Leiutis Pharmaceuticals Pvt. Ltd.
Publication of WO2016005995A2 publication Critical patent/WO2016005995A2/en
Publication of WO2016005995A3 publication Critical patent/WO2016005995A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to ready to use stable liquid pharmaceutical formulations of Bendamustine or a pharmaceutically acceptable salt thereof; wherein the formulation is devoid of glycols. Further the present invention relates to pharmaceutical composition of Bendamustine hydrochloride comprising of saccharide, suitable solvent or mixture of solvents and suitable adjuvants thereof.
PCT/IN2015/000279 2014-07-10 2015-07-09 Glycol free stable liquid compositions of bendamustine WO2016005995A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3414/CHE/2014 2014-07-10
IN3414CH2014 2014-07-10

Publications (2)

Publication Number Publication Date
WO2016005995A2 WO2016005995A2 (en) 2016-01-14
WO2016005995A3 true WO2016005995A3 (en) 2016-03-03

Family

ID=55065054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000279 WO2016005995A2 (en) 2014-07-10 2015-07-09 Glycol free stable liquid compositions of bendamustine

Country Status (1)

Country Link
WO (1) WO2016005995A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190151234A1 (en) * 2016-04-05 2019-05-23 Leiutis Pharmaceuticals Pvt. Ltd. Stable liquid pharmaceutical formulations of bendamustine
WO2020035806A1 (en) 2018-08-17 2020-02-20 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
IL297015A (en) * 2020-04-13 2022-12-01 US Nano Food & Drug INC Basic chemotherapeutic intratumour injection formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010063476A2 (en) * 2008-12-03 2010-06-10 Astellas Deutschland Gmbh Solid dosage forms of bendamustine
WO2011094565A1 (en) * 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010063476A2 (en) * 2008-12-03 2010-06-10 Astellas Deutschland Gmbh Solid dosage forms of bendamustine
WO2011094565A1 (en) * 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine

Also Published As

Publication number Publication date
WO2016005995A2 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
WO2017176620A3 (en) SOLUBLE C5aR ANTAGONISTS
EA201891099A1 (en) 7- (TIAZOL-5-IL) Pyrrolopyrimide as an agonist of the TLR7 receptor
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12018500904A1 (en) Peptide macrocycles against acinetobacter baumannii
EP4071149A3 (en) Heterocyclic compounds and uses thereof
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
MY187047A (en) Selective pyy compounds and uses thereof
BR112019024747A2 (en) fixed dose formulations
WO2018042362A9 (en) Muscarinic m1 receptor positive allosteric modulators
PH12018500377A1 (en) Novel annelated benzamides
WO2016005995A3 (en) Glycol free stable liquid compositions of bendamustine
SA518390920B1 (en) Novel annelated phenoxyacetamides
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
BR112017009510A2 (en) compositions comprising cyclosporine
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
EP3480186A4 (en) Novel aryl ethane derivative and pharmaceutical composition containing same as active ingredient
CA3003108A1 (en) Storage stable composition comprising rifaximin alpha
WO2015002755A3 (en) Compounds for the treatment of malaria
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2014030172A3 (en) Pharmaceutical formulations of rufinamide
WO2016022700A3 (en) Tlr-independent small molecule adjuvants
EP3626703A4 (en) Novel compound and pharmaceutical composition comprising same as active ingredient

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15819034

Country of ref document: EP

Kind code of ref document: A2